Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

288

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor Historically Known for High EphA2 Expression
Urothelial Cancer
Ovarian Cancer
Non-small Cell Lung Cancer
Head and Neck Cancer
Triple Negative Breast Cancer
Gastric/Upper Gastrointestinal Cancer

Interventions

DRUG: BT5528
DRUG: Nivolumab

Sponsor

BicycleTx Limited